News
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.
President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback